A5032767080- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Myasthenia Gravis and Thymoma
- Urinary and Genital Oncology Studies
- Multiple Myeloma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Ovarian cancer diagnosis and treatment
- Genetic factors in colorectal cancer
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
- COVID-19 and healthcare impacts
- Pleural and Pulmonary Diseases
- Cancer, Lipids, and Metabolism
- Oral health in cancer treatment
- Colorectal Cancer Treatments and Studies
- Epigenetics and DNA Methylation
- Lymphatic Disorders and Treatments
- Cancer Diagnosis and Treatment
University of Turin
2020-2025
Casa Sollievo della Sofferenza
2025
Istituti di Ricovero e Cura a Carattere Scientifico
2025
Ospedale San Luigi Gonzaga
2020-2024
Hospital Universitario 12 De Octubre
2023
Background/Objectives: The identification of driver mutations in NSCLC such as those the EGFR and KRAS genes has revolutionized understanding management many lung cancer patients opened up a new scenario early disease stages terms therapeutic options (EGFR) prognosis (KRAS). Data on prevalence rates stage distributions surgically resected are growing, but Southern Italy, estimation is limited, since upfront testing early-stage adenocarcinoma been only recently introduced according to current...
Lung cancer remains the leading cause of cancer-related death and it is usually diagnosed in advanced stages (stage III or IV). Recently, availability targeted strategies immunotherapy with checkpoint inhibitors (ICI) has favorably changed patient prognosis. Treatment outcome closely related to tumor biology interaction host immune microenvironment (TME). Whether for therapies response relies on presence specific genetic alterations cells, ICI accurate biomarkers are lacking clinical likely...
Neuroendocrine differentiation (NED) represents a possible androgen receptor pathway inhibitors (ARPI) resistance mechanism in metastatic castration prostate cancer (mCRPC). As mCRPC with NED has been excluded from clinical trials evaluating ARPI efficacy, this study investigates the prognostic impact of patients treated ARPIs. Methods: We retrospectively analyzed 327 patient data Enzalutamide or Abiraterone first and second successive lines treatment. was assessed using biopsy samples...
Safety data regarding BNT162b2 in cancer patients (CPs) are scarce. Herein we report the side effects (SEs), adverse events (AEs), and patient-reported outcomes (PROs) following administration CPs treated at San Luigi Gonzaga University Hospital. All who agreed to participate our vaccination campaign received were included descriptive analysis. An anonymous questionnaire investigating occurrence of SEs/AEs PROs was administered study population 21 days after first dose. Pearson's chi-squared...
Colorectal cancer is one of the most prevalent cancers nowadays. In metastatic setting, diagnosis and treatment have relied on tumor tissue analysis. However, different limitations this approach recently opened door to introduction liquid biopsy in clinical setting. Liquid provides real-time information about its heterogeneity a simple, non-invasive, repeatable way. There are several analytes that can be sought: exosomes, circulating cells, DNA, showing promising results areas early...
Pure red cell aplasia (PRCA) represents one of the most common paraneoplastic syndromes in patients with advanced thymoma. Ciclosporin is a very effective treatment this condition, and it seems to have also direct anti-cancer effect. We provide case radiological response thymoma associated total absence PRCA patient treated ciclosporin. A 60-year-old man underwent first-line chemotherapy, achieving partial disease followed by 2 years stable disease. After progression, developed PRCA, later...